Universal Beteiligungs und Servicegesellschaft mbH Invests $717,000 in Beam Therapeutics Inc. (NASDAQ:BEAM)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has invested approximately $717,000 in Beam Therapeutics, acquiring 36,707 shares of the company during the first quarter.
• Beam Therapeutics' stock price has seen a decline of 4.5%, with its market cap standing at $1.89 billion and recent earnings revealing a loss of ($1.24) EPS, missing analyst expectations.
• Despite recent challenges, Beam Therapeutics holds a consensus rating of "Buy" from analysts, with ten buy ratings and a target price averaging $48.75.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 36,707 shares of the company's stock, valued at approximately $717,000.

Other hedge funds also recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in shares of Beam Therapeutics in the 4th quarter valued at about $43,000. CWM LLC lifted its stake in Beam Therapeutics by 79.8% in the first quarter. CWM LLC now owns 2,684 shares of the company's stock valued at $52,000 after buying an additional 1,191 shares during the period. Sterling Capital Management LLC lifted its stake in Beam Therapeutics by 816.0% in the fourth quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock valued at $60,000 after buying an additional 2,146 shares during the period. Amalgamated Bank lifted its position in shares of Beam Therapeutics by 20.4% during the 1st quarter. Amalgamated Bank now owns 3,153 shares of the company's stock valued at $62,000 after acquiring an additional 534 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Beam Therapeutics during the 4th quarter valued at $191,000. Institutional investors and hedge funds own 99.68% of the company's stock.

Insider Activity

In other news, insider Fmr Llc sold 48,374 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $20.50, for a total transaction of $991,667.00. Following the transaction, the insider owned 2,073,665 shares of the company's stock, valued at approximately $42,510,132.50. The trade was a 2.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 49,624 shares of company stock worth $1,015,628. 3.50% of the stock is owned by corporate insiders.

Beam Therapeutics Stock Up 1.5%

Shares of NASDAQ BEAM traded up $0.29 during trading on Monday, reaching $19.12. The company had a trading volume of 1,586,884 shares, compared to its average volume of 2,045,214. The stock has a market cap of $1.92 billion, a PE ratio of -4.15 and a beta of 2.22. The business's 50-day moving average is $18.67 and its 200 day moving average is $21.17. Beam Therapeutics Inc. has a 12-month low of $13.52 and a 12-month high of $35.25.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.13). The company had revenue of $7.47 million during the quarter, compared to analysts' expectations of $14.69 million. Beam Therapeutics had a negative return on equity of 44.24% and a negative net margin of 609.24%. Beam Therapeutics's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm posted ($1.21) EPS. On average, analysts anticipate that Beam Therapeutics Inc. will post -4.57 earnings per share for the current year.

Wall Street Analyst Weigh In

BEAM has been the topic of a number of research reports. Wells Fargo & Company lowered their target price on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Cantor Fitzgerald raised shares of Beam Therapeutics to a "strong-buy" rating in a research report on Monday, July 21st. Guggenheim reduced their target price on Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Beam Therapeutics in a research report on Monday, April 7th. Finally, Barclays cut their price target on Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $48.75.

Beam Therapeutics Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.